Nanqiao Zheng

Title: Innovations of Nanqiao Zheng in Kinase Inhibitors

Introduction

Nanqiao Zheng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of five patents to his name, Zheng's work focuses on innovative compounds that have the potential to treat various diseases, including autoimmune disorders and cancers.

Latest Patents

Zheng's latest patents include groundbreaking compounds such as substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines. These compounds serve as inhibitors for kinases like TRK, c-MET, AXL, MER, and VEGFR2. The disclosed compounds exhibit strong inhibition activities and are intended for use in pharmaceutical compositions aimed at treating autoimmune diseases or cancers. Another notable patent involves oxazino-quinazoline and oxazino-quinoline type compounds, which also act as kinase inhibitors. This patent outlines the preparation methods and various uses of these compounds in drug development.

Career Highlights

Zheng is currently employed at Beijing Scitech-MQ Pharmaceuticals Limited, where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential impact on drug development and therapeutic applications.

Collaborations

Zheng collaborates with esteemed colleagues such as Qiang Zhang and Shannan Yu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Nanqiao Zheng's contributions to the field of kinase inhibitors highlight his role as a leading inventor in pharmaceutical research. His innovative compounds and collaborative efforts are paving the way for new treatments in medicine.